GAST and familial pancreatic carcinoma: As gastrin is a growth stimulant, a strategy against gastrin such as gastrazole is most likely to succeed in the settings of minimal tumour burden such as maintenance therapy after cytotoxic chemotherapy (although few drugs result in significant tumour shrinkage in pancreatic cancer) or adjuvant treatment.